The all-cash acquisition at a significant premium provides immediate and certain value for CPRX shareholders. The stock should trade near the deal price with a small spread reflecting closing risk (regulatory, shareholder vote). Monitor the proxy filing and HSR review timeline. The FIRDAPSE patent settlement removes a key overhang, extending IP protection to 2035.
Price Chart
Executive Summary
Catalyst Pharmaceuticals has entered into a definitive agreement to be acquired by Angelini Pharma S.p.A. for $31.50 per share in cash, representing a total equity value of approximately $4.1 billion. The transaction, unanimously approved by both boards, is expected to close in Q3 2026 and provides a 28% premium to the 30-day VWAP. Separately, Catalyst resolved all pending FIRDAPSE patent litigation with Hetero, pushing generic entry to no earlier than January 2035.
Key Facts
- Acquisition price of $31.50 per share in cash, total equity value ~$4.1 billion
- 28% premium to 30-day VWAP as of April 22, 2026; 21% premium to unaffected closing price
- Closing expected in Q3 2026, subject to stockholder approval, HSR, and other conditions
- All directors and executive officers entered into voting agreements to support the merger
- Termination fee of ~$155.5 million payable by Catalyst under specified circumstances
- FIRDAPSE patent litigation with Hetero settled; generic entry no earlier than January 2035
- Merger not subject to financing condition; Angelini financing via cash and debt with BNP Paribas as coordinator
- J.P. Morgan provided fairness opinion to Catalyst's board
Financial Impact
Total equity value of approximately $4.1 billion at $31.50 per share cash consideration
Risk Factors
- Shareholder vote may not be obtained (though insider voting agreements cover a significant block)
- Regulatory delays or antitrust conditions could push closing beyond Q3 2026 or impose remedies
- Superior proposal could emerge during the go-shop period, triggering termination fee
- Integration risk post-close for Angelini as a new U.S. market entrant
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-210587 |
| Document: 0001193125-26-210587-index-headers.html | 0001193125-26-210587 |
| Document: 0001193125-26-210587-index.html | 0001193125-26-210587 |
| Document: 0001193125-26-210587.txt | 0001193125-26-210587 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 22, 2026 5w ago | Institutional Cluster | — | awaiting T+5 | — | — |
Jul 24, 2026 9w ago | 15-12G | $31.49 awaiting T+5 | awaiting T+5 | — | — |
Jul 17, 2026 11w ago | EFFECT | $31.49 $31.49 | · 0.00% | ▼ −0.59% | — |
Jul 15, 2026 11w ago | 25-NSE | $31.49 $31.49 | · 0.00% | ▼ −0.98% | — |
Jul 8, 2026 12w ago | 8-K | $31.47 $31.49 | ▲ +0.06% | ▲ +0.20% | — |
Jun 30, 2026 13w ago | DEFA14A | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
Jun 30, 2026 13w ago | 8-K | $31.44 $31.49 | ▲ +0.16% | ▼ −0.10% | — |
May 28, 2026 18w ago | PREM14A | $31.23 $31.28 | ▲ +0.16% | ▲ +0.45% | — |
May 12, 2026 20w ago | DEFA14A | $31.14 $31.23 | ▲ +0.29% | ▲ +0.21% | — |
May 11, 2026 20w ago | Press Release | $31.14 $31.23 | ▼ −0.29% | ▼ −0.21% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access